Results 11 to 20 of about 103,481 (331)
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report [PDF]
European Psychiatry, 2022 Introduction We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa ...
M.L. Costa, A. Cerame
doaj +2 more sources
Pharmaceuticals, 2023 We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric +24 more
doaj +1 more source
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
Clinical Parkinsonism & Related Disorders, 2021 Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall +5 more
doaj +1 more source
Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]
PLoS ONE, 2014 BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko +4 more
doaj +1 more source
Alʹmanah Kliničeskoj Mediciny, 2023 The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj +1 more source
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources
Impulsivity in Patients with Parkinson’s Disease [PDF]
Journal of Biomedical & Clinical Research, 2017 In recent years focus has been increasingly placed on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD). ICDs include pathological attraction to gambling, compulsive shopping, compulsive eating and compulsive sexual behaviour and
Rumyana Kuzmanova +2 more
doaj +3 more sources
Cholinergic modulation of dopamine overflow in the rat neostriatum: A fast cyclic voltammetric study in vitro [PDF]
, 1994 Stimulus-evoked dopamine overflow in rat neostriatal slices was determined using fast cyclic voltammetry. The dopamine efflux induced by intrastriatal stimulation increased with stimulus intensity and was found to be enhanced by more than 100% upon ...
Kudernatsch, Martina, Sutor, Bernd
core +1 more source
Could dopamine agonists aid in drug development for anorexia nervosa? [PDF]
, 2014 Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage-years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight, and an often delusional quality ...
Frank, Guido KW
core +2 more sources
Predictors of dopamine agonist resistance in prolactinoma patients
BMC Endocrine Disorders, 2020 Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen +6 more
doaj +1 more source